Management Team
James Green
Chief Executive Officer
Mr. Green is the Chief Executive Officer of Vogenx and serves as Chairman of the Vogenx board of directors. James spent the early part of his career in banking where he advised on M&A and financing transactions. He then spent several years in various transaction related business development and finance roles at global pharmaceutical company GlaxoSmithKline. Prior to Vogenx, James was CEO of both public and private clinical stage drug development companies and developed an internal biotech investing platform at a pharmaceutical contract manufacturer. James holds a BBA and MBA.
William Wilkison, Ph.D.
Chief Scientific Officer
Dr. Wilkison is the Vogenx Chief Scientific Officer, Chair of the Company’s Scientific Advisory Board, and member of the Vogenx board of directors. Before joining Vogenx, Bill was a founder and senior executive at various private and public drug development companies where he was responsible for overall pipeline strategy and oversight of all research and development activities. Dr. Wilkison spent several years at GlaxoSmithKline in Worldwide Business Development and at predecessor companies studying metabolic disease where he was responsible for target and lead identification and development. Dr. Wilkison has published numerous peer-reviewed manuscripts in the metabolic disease area and is an inventor on several issued and pending patents. Dr. Wilkison holds a Ph.D. from Duke University Medical Center and did his postdoctoral work at Harvard Medical School.
Steven Delmar
Chief Financial Officer
Mr. Delmar serves as the Vogenx Chief Financial Officer and is a member of the Company’s board of directors. He has over two decades of public company CFO and executive management experience in the pharmaceutical, telecommunications, and software industries. During that time, Steve successfully led several debt and equity financings, including an IPO, and managed the execution and integration of multiple acquisitions and private equity sale transactions. Mr. Delmar earned a Bachelor of Science in Accounting from Clemson University and passed the CPA exam in Maryland.
Bentley Cheatham
Vice President of Research & Development
Dr. Cheatham is Vice President of Research and Development at Vogenx. Prior to his work in industry, he was an Assistant Professor and ran his own laboratory at the Joslin Diabetes Center at Harvard Medical School. Prior to Vogenx, Bentley held positions of increasing responsibility at multiple life sciences and drug development companies where his responsibilities ranged from developing and adapting early-stage platform technologies, to overseeing non-clinical and clinical development teams, as well as international alliance management. Dr. Cheatham established numerous NIH-funded drug discovery programs, has published numerous peer-reviewed articles in metabolic disease and is an inventor on several patents and pending patent applications. Bentley received his Ph.D. from the University of Tennessee and did his postdoctoral work at Harvard Medical School.
James Green
Chief Executive Officer
Mr. Green is the Chief Executive Officer of Vogenx and serves as Chairman of the Vogenx board of directors. James spent the early part of his career in banking where he advised on M&A and financing transactions. He then spent several years in various transaction related business development and finance roles at global pharmaceutical company GlaxoSmithKline. Prior to Vogenx, James was CEO of both public and private clinical stage drug development companies and developed an internal biotech investing platform at a pharmaceutical contract manufacturer. James holds a BBA and MBA.
William Wilkison, Ph.D.
Chief Scientific Officer
Dr. Wilkison is the Vogenx Chief Scientific Officer, Chair of the Company’s Scientific Advisory Board, and member of the Vogenx board of directors. Before joining Vogenx, Bill was a founder and senior executive at various private and public drug development companies where he was responsible for overall pipeline strategy and oversight of all research and development activities. Dr. Wilkison spent several years at GlaxoSmithKline in Worldwide Business Development and at predecessor companies studying metabolic disease where he was responsible for target and lead identification and development. Dr. Wilkison has published numerous peer-reviewed manuscripts in the metabolic disease area and is an inventor on several issued and pending patents. Dr. Wilkison holds a Ph.D. from Duke University Medical Center and did his postdoctoral work at Harvard Medical School.
Steven Delmar
Chief Financial Officer
Mr. Delmar serves as the Vogenx Chief Financial Officer and is a member of the Company’s board of directors. He has over two decades of public company CFO and executive management experience in the pharmaceutical, telecommunications, and software industries. During that time, Steve successfully led several debt and equity financings, including an IPO, and managed the execution and integration of multiple acquisitions and private equity sale transactions. Mr. Delmar earned a Bachelor of Science in Accounting from Clemson University and passed the CPA exam in Maryland.
Bentley Cheatham
Vice President of Research & Development
Dr. Cheatham is Vice President of Research and Development at Vogenx. Prior to his work in industry, he was an Assistant Professor and ran his own laboratory at the Joslin Diabetes Center at Harvard Medical School. Prior to Vogenx, Bentley held positions of increasing responsibility at multiple life sciences and drug development companies where his responsibilities ranged from developing and adapting early-stage platform technologies, to overseeing non-clinical and clinical development teams, as well as international alliance management. Dr. Cheatham established numerous NIH-funded drug discovery programs, has published numerous peer-reviewed articles in metabolic disease and is an inventor on several patents and pending patent applications. Bentley received his Ph.D. from the University of Tennessee and did his postdoctoral work at Harvard Medical School.
James Green
Chief Executive Officer
Mr. Green is the Chief Executive Officer of Vogenx and serves as Chairman of the Vogenx board of directors. James spent the early part of his career in banking where he advised on M&A and financing transactions. He then spent several years in various transaction related business development and finance roles at global pharmaceutical company GlaxoSmithKline. Prior to Vogenx, James was CEO of both public and private clinical stage drug development companies and developed an internal biotech investing platform at a pharmaceutical contract manufacturer. James holds a BBA and MBA.
William Wilkinson, Ph.D.
Chief Scientific Officer
Dr. Wilkison is the Vogenx Chief Scientific Officer, Chair of the Company’s Scientific Advisory Board, and member of the Vogenx board of directors. Before joining Vogenx, Bill was a founder and senior executive at various private and public drug development companies where he was responsible for overall pipeline strategy and oversight of all research and development activities. Dr. Wilkison spent several years at GlaxoSmithKline in Worldwide Business Development and at predecessor companies studying metabolic disease where he was responsible for target and lead identification and development. Dr. Wilkison has published numerous peer-reviewed manuscripts in the metabolic disease area and is an inventor on several issued and pending patents. Dr. Wilkison holds a Ph.D. from Duke University Medical Center and did his postdoctoral work at Harvard Medical School.
Steven Delmar
Chief Financial Officer
Mr. Delmar serves as the Vogenx Chief Financial Officer and is a member of the Company’s board of directors. He has over two decades of public company CFO and executive management experience in the pharmaceutical, telecommunications, and software industries. During that time, Steve successfully led several debt and equity financings, including an IPO, and managed the execution and integration of multiple acquisitions and private equity sale transactions. Mr. Delmar earned a Bachelor of Science in Accounting from Clemson University and passed the CPA exam in Maryland.
Bentley Cheatham
Vice President of Research & Development
Dr. Cheatham is Vice President of Research and Development at Vogenx. Prior to his work in industry, he was an Assistant Professor and ran his own laboratory at the Joslin Diabetes Center at Harvard Medical School. Prior to Vogenx, Bentley held positions of increasing responsibility at multiple life sciences and drug development companies where his responsibilities ranged from developing and adapting early-stage platform technologies, to overseeing non-clinical and clinical development teams, as well as international alliance management. Dr. Cheatham established numerous NIH-funded drug discovery programs, has published numerous peer-reviewed articles in metabolic disease and is an inventor on several patents and pending patent applications. Bentley received his Ph.D. from the University of Tennessee and did his postdoctoral work at Harvard Medical School.